Panacea Biotec announces successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll

Intimation of NCLT Order for Approval of Scheme

Intimation of Record Date

Termination of MOU with Refana

Disclosure under Regulation 30 of SEBI LODR Regulations, 2015

Related Party Disclosure for the half year ended

Disclosure of material impact of CoVID-19 pandemic on the Company

Disclosure under Regulation 30 of SEBI Regulations, 2015

Intimation for Postal Ballot Notice

Intimation sent to the Stock Exchanges for EGM to be held on